The State of China Biotech - Part III
Facts and Figures from ChinaBio -
VC Investments, M&A and IPO Activities
64 views
00:12:47 - Uploaded by Song Essinova, LLC on February 16, 2009
There has been much debate on the state of new drug development in China. Are there novel molecules being discovered there? What is the level of clinical trial activity? Are VCs investing in China? What about M&A and IPOs?
Greg Scott, President of ChinaBio, presents research data for 2008 for the first time, at an executive workshop held at Wilson Sonsini Goodrich & Rosati in San Francisco during the JP Morgan 27th Annual Healthcare Conference in January, 2009.
In this segment, Mr. Scott summarizes research findings on partnering, M&A, IPO and VC investment activities.
Tags: China, ChinaBio, Greg Scott, China biotech, partnering, M&A, IPO, VC
RELATED
COMMENTS
There are 0 comments. You must be logged in to comment.
Business & Finance
-
Stan Yakatan Views on the Biotech Industry
-
The Matchmaker for the pharmaceutical industry
-
The State of China Biotech 2010 - Part I
-
The State of China Biotech 2010 - Part II
-
The State of China Biotech 2010 - Part III
-
ChinaBio Accelerator
-
The State of China Biotech - Part I
-
The State of China Biotech - Part II
-
The State of China Biotech - Part III
